Joint financing supports Amylyx clinical trial for ALS treatment
The grant, which amounts to $2.96 million, comes from the ALS Accelerated Therapeutics Initiative (ALS ACT). This initiative is part of the two organizations as they seek to fund important advances for ALS patients around the world.
“To accelerate developing new treatments for ALS, the two foundations issued a global, competitive call for grant proposals for therapies that had a strong scientific rationale and where a biomarker of drug effect could be measured,” Dr. Merit Cudkowicz, chief medical officer for ALS Finding a Cure, said. “AMX0035 was chosen as one of the top new therapeutic candidates to bring forward for ALS.”
The trial is evaluating a new oral therapeutic candidate, AMX0035. This treatment combines sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). The new treatment shows that it is effective in animal and cellular models. The trial will continue to determine the effectiveness and safety of the treatment.
“The ALS Association is pleased to support this important clinical trial designed to incorporate biomarkers to track changes in the disease process,” Dr. Lucie Bruijn, chief scientist for The ALS Association, said. “Results from this trial will significantly contribute to biomarker development and inform us about the value of using this combined therapeutic approach.”
Organizations in this story
ALS Association 1275 K Street Northwest Washington, DC - 20005